New Delhi, India (PressExposure) October 18, 2011 -- St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the launch of the C7-XR Optical Coherence Tomography (OCT) Intravascular Imaging System with the C7 Dragonfly Imaging Catheter in India. OCT is a next-generation coronary imaging technology platform that aids physicians in the diagnosis and treatment of cardiovascular disease, and is used by interventional cardiologists to assist with stent selection and provide post-stenting information.
OCT technology utilizes near-infrared light to create images that go beyond older coronary imaging technologies - such as fluoroscopy and intravascular ultrasound (IVUS) - offering cardiologists an assessment method with enhanced clarity for their patients with coronary artery disease. With the technology, physicians can visualize and measure important vessel characteristics that are otherwise not visible or difficult to assess with the older imaging technology. Additionally, images are created with 10 times the resolution of intravascular ultrasound technology.
"OCT presents a new landmark in coronary imaging whereby we would be able to see micro structures in coronary arteries which provides diagnostic information that will help me to perform optimal angioplasty," said Dr. Ashok Seth, Chairman of the Fortis Group of Hospitals. "OCT technology can help me to see early and soft blockages which occur in younger patients and have high risk of causing heart attacks. The images make it almost feel as if the inside of the coronary artery was being seen with the naked eye."
The imaging capabilities assist physicians in stent selection by providing them with measurements of lesion length and vessel size and structure. Additionally, the OCT technology provides physicians with post-stenting positioning, potentially minimizing the need for repeat revascularization. At follow-up, the technology provides detailed information regarding the inner lining of the vessel and whether there is a recurrence of blood vessel narrowing, also known as stenosis.
According to Dr. Seth, in addition to helping determine stent size, OCT can also assist with stent placement, which he believes could help to improve short term and long term safety and improve patient results.
"St. Jude Medical is pleased to now offer Indian physicians our OCT technology," said Kaustav Banerjee, country manager of St. Jude Medical India. "We are the first company to offer this technology which helps to improve patient outcomes. We remain dedicated to the cardiovascular market with several other exciting products launching in the future."
The C7-XR System with the C7 Dragonfly Imaging Catheter was launched in Europe in May 2009 and follows the M3 OCT Imaging System. St. Jude Medical offers the only commercially available intracoronary OCT imaging device in the world. The C7-XR Coronary Imaging System is commercially available in the U.S, Europe and Australia.
About St. Jude Medical
St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. St. Jude Medical is headquartered in St. Paul, Minn. and has four major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. For more information, please visit http://sjm.com/
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company's control and the risk factors and other cautionary statements described in the Company's filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company's Annual Report on Form 10-K for the fiscal year ended January 1, 2011 and Quarterly Report on Form 10-Q for the fiscal quarter ended July 2, 2011. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.